NCT04697381View on ClinicalTrials.gov

Study of the Efficacy and Safety of Somatropin in Japanese Participants With PWS

PHASE3CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

February 9, 2021

Primary Completion Date

December 6, 2022

Study Completion Date

April 15, 2024

Conditions
Prader-Willi Syndrome
Interventions
BIOLOGICAL

somatropin - GH naïve pediatric cohort

somatropin 0.245 mg/kg/week

BIOLOGICAL

somatropin - GH treated cohort

somatropin 0.084 mg/kg/week

BIOLOGICAL

somatropin - adult cohort

somatropin 0.084 mg/kg/week

Trial Locations (5)

232-8555

Kanagawa Children's Medical Center, Yokohama

594-1101

Osaka Women's and Children's Hospital, Izumi

343-8555

Dokkyo Medical University Saitama Medical Center, Koshigaya

431-3192

Hamamatsu University Hospital, Hamamatsu

157-8535

National Center for Child Health and Development, Setagaya-ku

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT04697381 - Study of the Efficacy and Safety of Somatropin in Japanese Participants With PWS | Biotech Hunter | Biotech Hunter